Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 15;13(4):561.
doi: 10.3390/pharmaceutics13040561.

Convection Enhanced Delivery in the Setting of High-Grade Gliomas

Chibueze D Nwagwu  1 , Amanda V Immidisetti  2 , Michael Y Jiang  3 , Oluwasegun Adeagbo  1 , David C Adamson  4   5 , Anne-Marie Carbonell  6
Affiliations
Review

Convection Enhanced Delivery in the Setting of High-Grade Gliomas

Chibueze D Nwagwu et al. Pharmaceutics. .

Abstract

Development of effective treatments for high-grade glioma (HGG) is hampered by (1) the blood-brain barrier (BBB), (2) an infiltrative growth pattern, (3) rapid development of therapeutic resistance, and, in many cases, (4) dose-limiting toxicity due to systemic exposure. Convection-enhanced delivery (CED) has the potential to significantly limit systemic toxicity and increase therapeutic index by directly delivering homogenous drug concentrations to the site of disease. In this review, we present clinical experiences and preclinical developments of CED in the setting of high-grade gliomas.

Keywords: clinical trials; convection enhanced delivery; direct delivery; glioblastoma; high-grade glioma; neuro-oncology; refractory glioblastoma; refractory glioma.

PubMed Disclaimer

Conflict of interest statement

Anne-Marie Carbonell is the President and CEO of OncoSynergy, Inc. (manufacturer of OS2966) and holds an equity interest in the company. The rest of the authors declare no conflict of interest.

Figures

Figure 1
Figure 1
An example of an infusion performed by convection-enhanced delivery (CED) visualized on magnetic resonance imaging (MRI) with co-convected contrast. Images were obtained with permission from Dr. Michael Vogelbaum and Moffitt Cancer Center.
See this image and copyright information in PMC

References

    1. Ostrom Q.T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro. Oncol. 2020;22:iv1–iv96. - PMC - PubMed
    1. Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016;131:803–820. - PubMed
    1. Louis D.N., Wesseling P., Aldape K., Brat D.J., Capper D., Cree I.A., Eberhart C., Figarella-Branger D., Fouladi M., Fuller G.N., et al. cIMPACT-NOW update 6: New entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020;30:844–856. - PMC - PubMed
    1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005;352:987–996. - PubMed
    1. Jahangiri A., Chin A.T., Flanigan P.M., Chen R., Bankiewicz K., Aghi M.K. Convection-enhanced delivery in glioblastoma: A review of preclinical and clinical studies. J. Neurosurg. 2017;126:191–200. - PMC - PubMed

LinkOut - more resources